May 1979

Improvement in Tardive Dyskinesia After Muscimol Therapy

Author Affiliations

From the Department of Psychiatry, University of Chicago (Drs Tamminga and Crayton), and the Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Md (Dr Chase).

Arch Gen Psychiatry. 1979;36(5):595-598. doi:10.1001/archpsyc.1979.01780050105013

• Muscimol, thought to be a agonist of γ-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia. At oral dose levels from 5 to 9 mg, involuntary movements were consistently attenuated, usually in the absence of sedation. These results support the view that pharmacologic attempts to stimulate GABA-mediated synaptic transmission may afford symptomatic relief to patients with tardive dyskinesia.